Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 151 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H1 2015', provides an overview of the Ankylosing Spondylitis (Bekhterev's Disease)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ankylosing Spondylitis (Bekhterev's Disease)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Ankylosing Spondylitis (Bekhterev's Disease) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Ankylosing Spondylitis (Bekhterev's Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Ankylosing Spondylitis (Bekhterev's Disease) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Ankylosing Spondylitis (Bekhterev's Disease) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Ankylosing Spondylitis (Bekhterev's Disease) Overview 10
Therapeutics Development 11
Pipeline Products for Ankylosing Spondylitis (Bekhterev's Disease) - Overview 11
Pipeline Products for Ankylosing Spondylitis (Bekhterev's Disease) - Comparative Analysis 12
Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics under Development by Companies 13
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Ankylosing Spondylitis (Bekhterev's Disease) - Products under Development by Companies 20
Ankylosing Spondylitis (Bekhterev's Disease) - Companies Involved in Therapeutics Development 23
Amgen Inc. 23
Avesthagen Limited 24
BIOCAD 25
Biocon Limited 26
Boehringer Ingelheim GmbH 27
Celgene Corporation 28
Celltrion, Inc. 29
Covagen AG 30
Epirus Biopharmaceuticals, Inc. 31
Genor BioPharma Co., Ltd. 32
Inbiopro Solutions Pvt. Ltd. 33
Innovent Biologics, Inc. 34
Johnson & Johnson 35
Lupin Limited 36
Mabion SA 37
Momenta Pharmaceuticals, Inc. 38
Novartis AG 39
Oncobiologics, Inc. 40
Panacea Biotec Limited 41
Pfizer Inc. 42
Protalix BioTherapeutics, Inc. 43
Sandoz International GmbH 44
Shanghai Pharmaceutical Co., Ltd. 45
Therapeutic Proteins International, LLC 46
Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics Assessment 47
Assessment by Monotherapy Products 47
Assessment by Target 48
Assessment by Mechanism of Action 50
Assessment by Route of Administration 52
Assessment by Molecule Type 54
Drug Profiles 56
adalimumab biosimilar - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
adalimumab biosimilar - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
adalimumab biosimilar - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
adalimumab biosimilar - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
adalimumab biosimilar - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
adalimumab biosimilar - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
adalimumab biosimilar - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
adalimumab biosimilar - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
adalimumab biosimilar - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
apremilast - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
BI-655066 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
COVA-322 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
etanercept biosimilar - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
etanercept biosimilar - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
etanercept biosimilar - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
etanercept biosimilar - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
etanercept biosimilar - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
etanercept biosimilar - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
etanercept biosimilar - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
etanercept biosimilar - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
etanercept biosimilar - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
golimumab - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
golimumab biosimilar - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
IBI-303 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
IBPM-004AM - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
IBPM-005IX - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
infliximab biosimilar - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
infliximab biosimilar - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
infliximab biosimilar - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
infliximab biosimilar - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
infliximab biosimilar - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
infliximab biosimilar - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
INV-17 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
secukinumab - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
thalidomide - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
tofacitinib - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Ankylosing Spondylitis (Bekhterev's Disease) - Recent Pipeline Updates 103
Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects 137
Ankylosing Spondylitis (Bekhterev's Disease) - Discontinued Products 139
Ankylosing Spondylitis (Bekhterev's Disease) - Product Development Milestones 140
Featured News & Press Releases 140
Feb 16, 2015: Hospira launches first biosimilar monoclonal antibody Inflectra (infliximab) in major European markets 140
Nov 15, 2014: Novartis presents ground-breaking Phase III results showing AIN457 (secukinumab) significant efficacy in ankylosing spondylitis patients 141
Nov 10, 2014: Novartis to reveal landmark Phase III data for AIN457 (secukinumab) in psoriatic arthritis and ankylosing spondylitis at ACR 2014 141
Oct 23, 2014: Novartis AIN457 (secukinumab) meets primary endpoint in two Phase III studies in ankylosing spondylitis, a debilitating joint condition of the spine 143
Jul 09, 2014: Celgene Reports Results from the Phase III POSTURE Study Evaluating Oral OTEZLA in Ankylosing Spondylitis 144
Sep 11, 2013: Hospira's Inflectra the first biosimilar monoclonal antibody to be approved in Europe 144
Jun 27, 2013: Celltrion Healthcare Receives CHMP Positive Opinion For Remsima 146
May 31, 2013: Celltrion Provides Update On CT-P13 EU Approval Process 149
Mar 26, 2013: Celltrion Signs KRW88 Billion Contract With Celltrion Healthcare 149
Dec 14, 2012: Celltrion Signs KRW99 Billion Contract With Celltrion Healthcare 149
Appendix 150
Methodology 150
Coverage 150
Secondary Research 150
Primary Research 150
Expert Panel Validation 150
Contact Us 150
Disclaimer 151

List of Tables

Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H1 2015 11
Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease) - Comparative Analysis, H1 2015 12
Number of Products under Development by Companies, H1 2015 14
Number of Products under Development by Companies, H1 2015 (Contd..1) 15
Comparative Analysis by Late Stage Development, H1 2015 16
Comparative Analysis by Clinical Stage Development, H1 2015 17
Comparative Analysis by Early Stage Development, H1 2015 18
Comparative Analysis by Unknown Stage Development, H1 2015 19
Products under Development by Companies, H1 2015 20
Products under Development by Companies, H1 2015 (Contd..1) 21
Products under Development by Companies, H1 2015 (Contd..2) 22
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Amgen Inc., H1 2015 23
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Avesthagen Limited, H1 2015 24
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by BIOCAD, H1 2015 25
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Biocon Limited, H1 2015 26
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Boehringer Ingelheim GmbH, H1 2015 27
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Celgene Corporation, H1 2015 28
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Celltrion, Inc., H1 2015 29
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Covagen AG, H1 2015 30
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 31
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Genor BioPharma Co., Ltd., H1 2015 32
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015 33
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Innovent Biologics, Inc., H1 2015 34
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Johnson & Johnson, H1 2015 35
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Lupin Limited, H1 2015 36
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Mabion SA, H1 2015 37
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Momenta Pharmaceuticals, Inc., H1 2015 38
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Novartis AG, H1 2015 39
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Oncobiologics, Inc., H1 2015 40
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Panacea Biotec Limited, H1 2015 41
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Pfizer Inc., H1 2015 42
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Protalix BioTherapeutics, Inc., H1 2015 43
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Sandoz International GmbH, H1 2015 44
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Shanghai Pharmaceutical Co., Ltd., H1 2015 45
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Therapeutic Proteins International, LLC, H1 2015 46
Assessment by Monotherapy Products, H1 2015 47
Number of Products by Stage and Target, H1 2015 49
Number of Products by Stage and Mechanism of Action, H1 2015 51
Number of Products by Stage and Route of Administration, H1 2015 53
Number of Products by Stage and Molecule Type, H1 2015 55
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics - Recent Pipeline Updates, H1 2015 103
Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects, H1 2015 137
Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects (Contd..1), H1 2015 138
Ankylosing Spondylitis (Bekhterev's Disease) - Discontinued Products, H1 2015 139